Nancy A. Sachs

A frameshift mutation in Disrupted in Schizophrenia 1 in an American family with schizophrenia and schizoaffective disorder

Nancy A. Sachs, Akira Sawa, Susan E. Holmes et al. · Molecular Psychiatry · 2005 · 222 citations

Psychiatry, Risk Prediction, Schizophrenia 1 +12

<i>In Vitro</i>Characterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor

Ming‐Tain Lai, Meizhen Feng, Jean‐Pierre Falgueyret et al. · Antimicrobial Agents and Chemotherapy · 2013 · 140 citations · Full text

The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents

P.H. Hutson, Eleftheria N. Finger, Brian C. Magliaro et al. · Neuropharmacology · 2011 · 139 citations

Synaptic Plasticity, Medicine, Synaptic Transmission +9

Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations

Meizhen Feng, Nancy A. Sachs, Min Xu et al. · Antimicrobial Agents and Chemotherapy · 2016 · 92 citations · Full text

Clinical Trough Concentration, Reverse Transcriptase Inhibitor, Medicine +13

Differential ergoline and ergopeptine binding to 5-hydroxytryptamine2A receptors: ergolines require an aromatic residue at position 340 for high affinity binding.

M S Choudhary, Nancy A. Sachs, Ahmet Uluer et al. · Molecular Pharmacology · 1995 · 91 citations